Related coverage linked through entity extraction aliases.
Apr 25, 2026
A new U.S. clinical study will test whether provider-mediated communication of colorectal cancer genetic risk increases family genetic testing. The trial plans to enroll around 4,000 patients and relatives.
Apr 23, 2026
Merck is expanding its AI efforts through partnerships with Google Cloud and Mayo Clinic. The company said it will deploy AI across R&D and use multimodal clinical datasets to support drug discovery and precision medicine.
Apr 23, 2026
MSD signed a Google Cloud agreement worth up to $1 billion and entered an AI-focused R&D collaboration with Mayo Clinic. The deals expand AI use in drug discovery, development and broader operations.
Apr 11, 2026
Q1 2026 sleep medicine trends include broader use of AI, expanding obstructive sleep apnea and narcolepsy treatments, and policy changes affecting reimbursement and access.
Apr 04, 2026
A clinical study in Shock found that Nu.Q H3.1 and H3R8 Citrulline were significantly elevated in 674 trauma patients, especially those who developed VTE. The findings point to potential clinical utility for trauma care and support commercialization of Nu.Q NETs.
Mar 25, 2026
Research shows chloramine disinfection successfully stopped a Legionnaires' disease outbreak in Minnesota, while clinical data reveals Legionella pneumonia has 11.9% 30-day mortality and disproportionately affects immunocompromised patients. The studies highlight both prevention strategies and diagnostic challenges.
Mar 23, 2026
A new four-marker blood test detects pancreatic cancer with 91.9% accuracy across all stages and 87.5% accuracy for early-stage disease. The test combines two newly identified proteins with existing biomarkers and can differentiate cancer from non-cancerous conditions. While promising for pancreatic cancer, most cancers still cannot be reliably diagnosed with blood tests alone.
Mar 21, 2026
Colorectal cancer diagnoses in people under 50 now account for nearly half of all new cases, prompting specialized treatment programs that use precision medicine and liquid biopsy technology to customize care based on individual tumor genetics.
Mar 18, 2026
Mayo Clinic is pursuing two distinct nanoparticle-based cancer treatments: milk-derived nanoparticles for targeted gene therapy in bile duct cancer, and magnetic nanoparticle hyperthermia for metastatic solid tumors.
Mar 17, 2026
Over 25 companies are developing 30+ therapies for celiac disease, with recent positive trial results and FDA Fast Track designation. A new blood test using T-cell receptor sequencing may enable noninvasive diagnosis and monitoring.
Mar 17, 2026
Mayo Clinic researchers found that Brigatinib, an FDA-approved lung cancer drug, can block survival pathways in ovarian cancer cells when combined with PARP inhibitors, potentially overcoming treatment resistance.
Mar 05, 2026
Whole genome sequencing, comprehensive genomic profiling, and spatial multiomics are transforming precision medicine from research tools to clinical applications in oncology, rare diseases, and neonatal care, enabling faster diagnoses and personalized treatments.
Feb 27, 2026
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
Feb 25, 2026
The FDA approved acalabrutinib combined with venetoclax for chronic lymphocytic leukemia and small lymphocytic leukemia based on phase III trial results. Separately, Yale researchers identified CD25 protein complex as a new drug target for aggressive leukemias.
Feb 23, 2026
Merck and Mayo Clinic announced a research collaboration allowing Merck to use AI and advanced analytics with Mayo's clinical and genomic datasets for drug discovery, initially focusing on dermatology, neurology, and gastroenterology.
Feb 20, 2026
Barclays initiated coverage on Merck with an overweight rating and $140 price target, citing expected product launches including enlicitide and pivotal trial readouts for tulisokibart in 2026.
Feb 18, 2026
Merck announced a strategic collaboration with Mayo Clinic to leverage AI and advanced analytics in drug discovery, focusing initially on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.
Feb 18, 2026
Merck and Mayo Clinic announced a research agreement on February 18, 2026, to integrate AI and advanced analytics into drug discovery, initially targeting inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.
Feb 18, 2026
Merck and Mayo Clinic announced a research and development agreement to apply artificial intelligence and multimodal clinical data to support drug discovery and development, marking Mayo Clinic's first strategic collaboration of this scale with a global biopharmaceutical company.
Feb 18, 2026
Merck and Mayo Clinic announced a research and development agreement to apply artificial intelligence, advanced analytics and multimodal clinical data to support drug discovery and development, marking Mayo Clinic's first strategic collaboration of this scale with a global biopharmaceutical company.
